SOLUTION / PUBLIC SOURCE RECORD
Vistin Pharma: sustainable production of high-quality Metformin
- Published 14 May 2025; updated 23 March 2026; estimated reading time 3 minutes. Marked available worldwide; listed under Health and life science / Biopharma and Industrial production.
- Vistin Pharma manufactures metformin hydrochloride in active pharmaceutical ingredient (API) and direct-compression (DC) forms, including granules. The page describes metformin as a first-line treatment for type 2 diabetes. Vistin says its Norway plant supplies approximately 10% of global demand for metformin HCl API, serving pharmaceutical companies that sell in more than 100 countries.
- The company describes its product as high-purity and free-flowing, with no detectable nitrosamines and very low residual DMA (Impurity F). These are manufacturer-reported product qualities; the page does not provide analytical methods or independent certificates.
- Vistin says production uses 100% renewable hydropower. It reports recycling 80% of fresh-water consumption, reducing volatile organic compound emissions to air by 95% over five years, and zero waste discharge to water sources or the ocean. These are company sustainability figures; the page does not identify the baselines or measurement periods beyond the VOC comparison.
- The article says Vistin has produced metformin since 1969 and recently completed an expansion intended to raise its global market share to 15%. It reports regulatory authorisations in Norway, the US, Brazil, Japan, South Korea and other markets, and identifies Asia and the Americas as growth targets.
- The page cites an IDF projection that 853 million people (about one in eight adults) could be living with diabetes by 2050, 46% above its “today” baseline. This is a dated projection and should not be read as current epidemiological guidance.
- Linked to SDGs 3, 6 and 12. Case-study links include the 2024 sustainability report and annual report.
- Contact: Sabrina Berge, Global Sales Manager, Sabrina.berge@vistin.com. Company: VISTIN PHARMA AS, Østensjøveien 27, 0661 Oslo, Norway; vistin.com.